2. Academic Validation
  3. SAH derived potent and selective EZH2 inhibitors

SAH derived potent and selective EZH2 inhibitors

  • Bioorg Med Chem Lett. 2015 Apr 1;25(7):1532-7. doi: 10.1016/j.bmcl.2015.02.017.
Pei-Pei Kung 1,  Buwen Huang 1,  Luke Zehnder 1,  John Tatlock 1,  Patrick Bingham 2,  Cody Krivacic 2,  Ketan Gajiwala 1,  Wade Diehl 1,  Xiu Yu 1,  Karen A Maegley 2
Affiliations

Affiliations

  • 1 Oncology Chemistry, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Dr., San Diego, CA 92121, USA.
  • 2 Oncology Research Unit, Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Dr., San Diego, CA 92121, USA.
PMID: 25746813 DOI: 10.1016/j.bmcl.2015.02.017
Abstract

A series of novel enhancer of zeste homolog 2 (EZH2) inhibitors was designed based on the chemical structure of the Histone Methyltransferase (HMT) inhibitor SAH (S-adenosyl-l-homocysteine). These nucleoside-based EZH2 inhibitors blocked the methylation of nucleosomes at H3K27 in biochemical assays employing both WT PRC2 complex as well as a Y641N mutant PRC2 complex. The most potent compound, 27, displayed IC50's against both complexes of 270 nM and 70 nM, respectively. To our knowledge, compound 27 is the most potent SAH-derived inhibitor of the EZH2 PRC2 complex yet identified. This compound also displayed improved potency, lipophilic efficiency (LipE), and selectivity profile against Other lysine methyltransferases compared with SAH.

Keywords

EZH2; Homology model; Nucleoside; SAH.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z